Latest Viking Therapeutics News & Updates

See the latest news and media coverage for Viking Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Viking Therapeutics

Biopharmaceutical company developing therapeutics for metabolic and endocrine disorders

vikingtherapeutics.com

Headquarters: San Diego, United States
Founded year: 2012
Company type: Public company
Number of employees: 50–200

Last updated Today

Latest news about Viking Therapeutics

In short: Viking Therapeutics reported a $158.3 million Q1 loss while advancing its obesity drug pipeline and appointing Dr. Hubert C. Chen as CMO.

Company announcements

April 29 Viking Therapeutics

Viking Therapeutics reports Q1 2026 financial results

VANQUISH-1 and -2 trials fully enrolled. Oral VK2735 Phase 3 starts 4Q26. Cash at $603M. Net loss $158.3M.

March 26 Viking Therapeutics

Viking Therapeutics completes enrollment in VK2735 Phase 3 VANQUISH-2 trial

The 78-week study evaluates subcutaneous VK2735 in adults with obesity and type 2 diabetes. About 1,000 patients were randomized to doses or placebo.

February 11 Viking Therapeutics

Viking Therapeutics reports Q4 and year-end 2025 financial results

Announces Phase 3 progress for VK2735 in obesity, plans oral VK2735 Phase 3 in 3Q26, and holds $706M cash. Net loss was $157.7M for Q4 and $358.5M for the year.

January 12 Viking Therapeutics

Viking Therapeutics announces publication of Phase 2 VENTURE trial results

VK2735 shows up to 14.7% weight loss after 13 weeks with no plateau. VK2735 advances in Phase 3 VANQUISH trials.

Media coverage

Today Yahoo Finance

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu...

June 8 Yahoo Finance

3 potential takeover targets in obesity

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a...

June 7 The Globe and Mail

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.

June 3 Axios

The obesity drug race moves beyond weight loss

The next winners may be determined by whether patients keep taking treatments long enough to benefit.

Never miss news about Viking Therapeutics

Track Viking Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Viking Therapeutics competitors & trending companies

Browse news for competitors to Viking Therapeutics and other trending companies.